Comparing the effectiveness of hyperimmune plasma and plasmapheresis in COVID-19 patients

IF 0.2 Q4 UROLOGY & NEPHROLOGY

Journal of Renal Injury Prevention Pub Date : 2023-12-04 DOI:10.34172/jrip.2023.32185

Neda Sadat Ahmadi, H. Samimagham, Mehdi Hassaniazad, Fatemeh Khajavi-Mayvan, MohammadHosein Sheybani-Arani, Ali Salimi Asl, Mitra Kazemi Jahromi

{"title":"Comparing the effectiveness of hyperimmune plasma and plasmapheresis in COVID-19 patients","authors":"Neda Sadat Ahmadi, H. Samimagham, Mehdi Hassaniazad, Fatemeh Khajavi-Mayvan, MohammadHosein Sheybani-Arani, Ali Salimi Asl, Mitra Kazemi Jahromi","doi":"10.34172/jrip.2023.32185","DOIUrl":null,"url":null,"abstract":"Introduction: In December 2019, the first clinical signs of patients infected with SARS CoV 2 surfaced, then the fatality rate rose daily with no available definitive therapy. Objectives: Considering the necessity for more research into plasma therapy, the urgency of treating patients with a severe disease, and the lack of comparable studies, we compared the effectiveness of hyperimmune plasma and plasmapheresis in COVID-19 patients. Patients and Methods: In this quasi-experimental study, 38 patients with severe COVID-19 were enrolled in two groups of 19 individuals treated with plasmapheresis and hyperimmune plasma after matching for severity. The researcher documented the patient’s information on a checklist submitted for statistical analysis using the SPSS software. Results: Patients comprised 60.53% of men and 39.5% of women. In this study, 60.53% of patients had underlying conditions, including hypertension and diabetes. The mean length of hospitalization for patients in the hyperimmune plasma group was considerably shorter than those in the plasmapheresis group (P<0.05). Conclusion: The average hospitalization time for patients who received hyperimmune plasma was considerably shorter than the plasmapheresis group. As a result, patients are encouraged to utilize this type of plasma at the earliest stages of the condition.","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":"27 6","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2023-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Renal Injury Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/jrip.2023.32185","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: In December 2019, the first clinical signs of patients infected with SARS CoV 2 surfaced, then the fatality rate rose daily with no available definitive therapy. Objectives: Considering the necessity for more research into plasma therapy, the urgency of treating patients with a severe disease, and the lack of comparable studies, we compared the effectiveness of hyperimmune plasma and plasmapheresis in COVID-19 patients. Patients and Methods: In this quasi-experimental study, 38 patients with severe COVID-19 were enrolled in two groups of 19 individuals treated with plasmapheresis and hyperimmune plasma after matching for severity. The researcher documented the patient’s information on a checklist submitted for statistical analysis using the SPSS software. Results: Patients comprised 60.53% of men and 39.5% of women. In this study, 60.53% of patients had underlying conditions, including hypertension and diabetes. The mean length of hospitalization for patients in the hyperimmune plasma group was considerably shorter than those in the plasmapheresis group (P<0.05). Conclusion: The average hospitalization time for patients who received hyperimmune plasma was considerably shorter than the plasmapheresis group. As a result, patients are encouraged to utilize this type of plasma at the earliest stages of the condition.

查看原文本刊更多论文

比较超免疫血浆和血浆置换术对 COVID-19 患者的疗效

2019年12月，SARS冠状病毒感染患者首次出现临床症状，随后病死率逐日上升，目前尚无明确的治疗方法。目的:考虑到需要更多的血浆治疗研究，治疗重症患者的紧迫性，以及缺乏可比研究，我们比较了高免疫血浆和血浆置换在COVID-19患者中的疗效。患者与方法:在这项准实验研究中，38例重症COVID-19患者在严重程度匹配后，分为两组，每组19人接受血浆置换和高免疫血浆治疗。研究人员将患者的信息记录在提交给SPSS软件进行统计分析的检查表上。结果:男性占60.53%，女性占39.5%。在本研究中，60.53%的患者有高血压和糖尿病等基础疾病。高免疫血浆组患者的平均住院时间明显短于血浆置换组(P<0.05)。结论:高免疫血浆组患者平均住院时间明显短于血浆置换组。因此，鼓励患者在病情的早期阶段使用这种类型的血浆。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Renal Injury Prevention UROLOGY & NEPHROLOGY-

CiteScore

1.60

自引率

0.00%

发文量

期刊介绍： The Journal of Renal Injury Prevention (JRIP) is a quarterly peer-reviewed international journal devoted to the promotion of early diagnosis and prevention of renal diseases. It publishes in March, June, September and December of each year. It has pursued this aim through publishing editorials, original research articles, reviews, mini-reviews, commentaries, letters to the editor, hypothesis, case reports, epidemiology and prevention, news and views and renal biopsy teaching point. In this journal, particular emphasis is given to research, both experimental and clinical, aimed at protection/prevention of renal failure and modalities in the treatment of diabetic nephropathy. A further aim of this journal is to emphasize and strengthen the link between renal pathologists/nephropathologists and nephrologists. In addition, JRIP welcomes basic biomedical as well as pharmaceutical scientific research applied to clinical nephrology. Futuristic conceptual hypothesis that integrate various fields of acute kidney injury and renal tubular cell protection are encouraged to be submitted.